147406-22-2

Basic information

• Product Name: 1-(3,4-DIMETHOXYPHENYL)CYCLOBUTANECARBOXYLIC ACID
• Synonyms: 1-(3,4-DIMETHOXYPHENYL)CYCLOBUTANECARBOXYLIC ACID;1-(3,4-DIMETHOXYPHENYL)CYCLOBUTANE-1-CARBOXYLIC ACID;AKOS BBV-004989
• CAS NO: 147406-22-2
• Molecular Formula: C13H16O4
• Molecular Weight: 236.26
• Mol File: 147406-22-2.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-(3,4-DIMETHOXYPHENYL)CYCLOBUTANECARBOXYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(3,4-DIMETHOXYPHENYL)CYCLOBUTANECARBOXYLIC ACID(147406-22-2)
• EPA Substance Registry System: 1-(3,4-DIMETHOXYPHENYL)CYCLOBUTANECARBOXYLIC ACID(147406-22-2)

Safety Data

• Hazardous Substances Data: 147406-22-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1-(3,4-DIMETHOXYPHENYL)CYCLOBUTANECARBOXYLIC ACID is used as a therapeutic agent for its potential anti-inflammatory and analgesic properties. Its unique chemical structure allows it to be a promising candidate for the development of new drugs targeting inflammation and pain relief.
Used in Chemical Synthesis:
1-(3,4-DIMETHOXYPHENYL)CYCLOBUTANECARBOXYLIC ACID is used as a versatile building block for the synthesis of various biologically active molecules. Its chemical structure provides a foundation for creating new compounds with potential applications in the pharmaceutical, medical, and chemical industries.

Upstream product

• 147406-21-1 1-(3,4-dimethoxyphenyl)cyclobutanecarbonitrile 
• 93-17-4 3,4-dimethoxyphenylacetonitrile 

Relevant articles and documents

Synthesis method of arylcyclobutane compound

The present invention discloses a method for synthesizing an arylcyclobutane compound to 1eq phenylacetonitrile and 1.1eq 1-bromo-3-chloropropane as raw material, N,N- dimethylacetamide as a solvent, plus 2.5eq sodium hydride, under the protection of iner

Discovery of Conformationally Restricted Human Glutaminyl Cyclase Inhibitors as Potent Anti-Alzheimer's Agents by Structure-Based Design

Alzheimer's disease (AD) is an incurable, progressive neurodegenerative disease whose pathogenesis cannot be defined by one single element but consists of various factors; thus, there is a call for alternative approaches to tackle the multifaceted aspects of AD. Among the potential alternative targets, we aim to focus on glutaminyl cyclase (QC), which reduces the toxic pyroform of β-amyloid in the brains of AD patients. On the basis of a putative active conformation of the prototype inhibitor 1, a series of N-substituted thiourea, urea, and α-substituted amide derivatives were developed. The structure-activity relationship analyses indicated that conformationally restrained inhibitors demonstrated much improved QC inhibition in vitro compared to nonrestricted analogues, and several selected compounds demonstrated desirable therapeutic activity in an AD mouse model. The conformational analysis of a representative inhibitor indicated that the inhibitor appeared to maintain the Z-E conformation at the active site, as it is critical for its potent activity.

Multidrug resistance modifying dithianes

Compounds of the formula STR1 wherein R is a residue of the formula STR2 and R1, R2, R3, R4, R5, R6, R7, X, Y and Z are as described, with the exception of rac-N-(3,4-dimethoxyphenethyl)-2-(3,4-dimethoxyphenyl)-β,N-dimethyl-m-dithiane-2-propanamine, as well as their acid addition salts, in particular for use in eliminating cytostatic resistance in tumor treatment and chloroquine resistance in malaria.